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Molecularly Targeted Therapy Using
Bevacizumab for Non-Small Cell Lung
Cancer: a Pilot Study for the New CT
Response Criteria
Objective: We wanted to compare the efficacy of the new CT response evalua-
tion criteria for predicting the tumor progression-free survival (PFS) with that of
RECIST 1.1 in non-small cell lung cancer (NSCLC) patients who were treated
with bevacizumab. 
Materials and Methods: Sixteen patients (M:F = 11:5; median age, 57 years)
treated with bevacizumab and combined cytotoxic chemotherapeutic agents
were selected for a retrospective analysis. The tumor response was assessed by
four different methods, namely, by using RECIST 1.1 (RECIST), RECIST but
measuring only the solid component of tumor (RECISTsolid), the alternative
method reflecting tumor cavitation (the alternative method) and the combined cri-
teria (the combined criteria) that evaluated both the changes of tumor size and
attenuation. To evaluate the capabilities of the different measurement methods to
predict the patient prognosis, the PFS were compared, using the log rank test,
among the responder groups (complete response [CR], partial response [PR],
stable disease [SD] and progressive disease [PD]) in terms of the four different
methods. 
Results: The overall (CR, PR or SD) response rates according to RECIST,
RECISTsolid, the alternative method and the combined criteria were 81%, 88%,
81% and 85%, respectively. The confirmed response rates (CR or PR) were
19%, 19%, 50% and 54%, respectively. Although statistically not significant, the
alternative method showed the biggest difference for predicting PFS among the
three response groups (PR, SD and PD) (p = 0.07). RECIST and the alternative
method showed a significant difference for predicting the prognosis between the
good (PR or SD) and poor overall responders (p = 0.02). 
Conclusion: The response outcome evaluations using the three different CT
response criteria that reflect tumor cavitation, the ground-glass opacity  compo-
nent and the attenuation changes in NSCLC patients treated with bevacizumab
showed different results from that with using the traditional RECIST method. 
ccurately assessing the changes of the tumor burden is important when
conducting cancer therapy, and so much effort has been directed toward
the development of standardized and reproducible methods for evaluat-
ing the response of tumors. The Initial Response Evaluation Criteria in Solid Tumors
(RECIST) published in 2000 (1) has been widely used in the scientific oncology
community. The revised RECIST guidelines (version 1.1) were developed for current
use (2). However, a number of questions and issues (e.g., tumor size changes only, not
considering various morphologic changes within the target lesions with treatment)
have been raised about the use of the traditional tumor response criteria, including the
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e-mail: kyungs.lee@samsung.com Arevised version 1.1. Particularly, the concern over the
applicability of the RECIST criteria has been focused on
the trials of molecularly targeted non-cytotoxic drugs,
including angiogenesis inhibitors (2-5). 
There are diverse tumor response patterns in non-small
cell lung cancer (NSCLC) that is treated with vascular
endothelial growth factor (VEGF) receptor inhibitor and
platinum-based chemotherapy. Crabb et al. (3) observed
cases that showed the appearance of cavitation and this
implied there was a tumor response during the treatment
of NSCLC with angiogenesis inhibitor plus chemothera-
peutic agents. They proposed that the response assessment
might be improved by incorporating cavitation into the
volume assessment of target lesions, which potentially
alters the outcome of key efficacy parameters in clinical
trials. In another study on gastrointestinal stromal tumors
(GISTs) that were treated with imatinib (4), dramatic
changes were noted in the tumor attenuation values (due
to tumor necrosis) after the treatment, as determined by
measuring the CT attenuation coefficient (Hounsfield unit
[HU]) on the contrast enhanced CT images. The authors of
that study recommended incorporating the tumor attenua-
tion changes in addition to the tumor size changes for
tumor response evaluation. 
In addition to size changes, cavitation and attenuation
changes within a tumor (due to tumor necrosis and
hemorrhage) are also tumor events in response to
anticancer chemotherapy, and particularly to molecularly
targeted non-cytotoxic drugs. The idea of diverse tumor
responses to anticancer therapy prompted us to devise
more appropriate CT response criteria than the conven-
tional criteria to enhance predicting the disease progression
free survival (PFS) in patients with NSCLC. Thus, the
purpose of our study was, as a pilot study, to compare the
efficacy of the CT response evaluation criteria (reflecting
tumor cavitation, a ground-glass opacity [GGO]
component and attenuation changes) for the prediction of
tumor PFS with that of the RECIST 1.1 for NSCLC




Our Institutional Review Board approved our retrospec-
tive study with a waiver of informed consent; written
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Fig. 1. RECIST versus RECIST for
measuring only solid portion
(RECISTsolid). 
A. Diagram depicting target lesion
measurement by RECIST and
RECISTsolid.
B, C. Solid component within partly solid
nodule has disappeared after treatment,
but ground-glass component of lesion is
still remaining (patient No. 8). informed consent was acquired for the use of CT scans for
all the patients. 
We acquired the patients’ data from the prospective
Phase II clinical trial of Bevacizumab as a salvage
treatment for NSCLC, which was conducted at our institu-
tion during the period from May 2006 to July 2009. A
total of 21 patients with metastatic or recurrent NSCLC
and who were treated with bevacizumab (at a dose of 15
mg/kg on day 1) combined with cytotoxic chemotherapeu-
tic agents (gemcitabine 1000 mg/m
2 IV on days 1 and 8,
and cisplatin 70 mg/m
2 IV on day 1), were selected for this
study. We excluded those patients (n = 2) who had not
undergone post-treatment CT at our institution, or those (n
= 3) who had no measurable disease on the pre-treatment
CT. Ultimately, 16 patients (M:F = 11:5; median age, 57
years) were enrolled in this study. The median follow-up
time was 7.9 months (range, 0.9-32.6 months).
CT Technique
The initial CT scans were performed within two weeks
before starting chemotherapy, and the follow-up CT scans
were conducted after two cycles of chemotherapy. For all
the patients, the CT studies were obtained with a 64-
detector (LightSpeed VCT XT, GE Healthcare, WI) row
scanner and using the helical technique (125 mA, 120 kVp,
a beam width of 10-20 mm, a beam pitch of 1.375-1.5).
The scans covered from the lung apices to the level of the
middle portion of both kidneys. Scanning was started 90
seconds after the intravenous injection of contrast medium
(a total of 80 mL of Iomeron 300 [Iomeprol]; Bracco;
Milan, Italy). The contrast medium was infused at a rate of
3 mL/s and by using a power injector (MCT Plus; Medrad;
Pittsburgh, PA). The image data was reconstructed with a
2.5-mm section thickness. For the mediastinal window
images, the image data was reconstructed with a soft-tissue
algorithm, and for lung window images, the data was
reconstructed with a bone algorithm. The reconstructed
images were directly interfaced with a picture archiving
and communication systems (PACS) (PathSpeed or
Centricity 2.0; GE Healthcare, Mt. Prospect, IL), which
displayed all the image data on two monitors (a 1536 ×
2048 matrix, an 8-bit viewable gray scale and 60-ft-
Lambert luminescence). Both the mediastinal (width: 400
HU, level: 20 HU) and lung (width: 1500 HU, level: 
-700 HU) window images were viewed on these monitors.
Image Evaluation
Two chest radiologists (both with five years of CT
Lee et al.
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Fig. 2. Response evaluation using
alternative method. 
A. Diagram depicting target lesion
measurement by RECIST and alterna-
tive method.
B, C. CT images demonstrating
pulmonary cavitation after two cycles of
Bevacizumab-containing chemotherapy;
CT images at baseline (B) and after two
cycles of bevacizumab (C). There is no
residual solid component within lesion.
Tumor response was assessed as
stable disease according to traditional
RECIST. In contrast, it corresponds to
partial response by alternative method
(patient No. 9).interpretation experience) and who were blinded to the
clinical details and outcomes independently evaluated the
CT images. The size of the target lesion was measured on
the initial and follow-up CT scans at the level of the lesion
equator (the longest diameter on the largest target lesion
image plane). They recorded the changes in the size of the
target lesion before and after the therapy once with includ-
ing both the solid and GGO components (on lung window
images) of the lesion ([RECIST guidelines version 1.1],
designated as RECIST) and then at the other time with
including only the solid component on the mediastinal
window images of the lesion (designated as RECISTsolid)
(6) (Fig. 1). Each target lesion was classified as being either
cavitated or not cavitated. In a cavitary lesion, only the
soft-tissue wall thickness, except the cavitary area, was
measured as the tumor size (designated as the alternative
measurement), that is, we subtracted the cavity diameter
(zero if no cavity was present) from the longest diameter
of the target lesion (3) (Fig. 2). Each measurement was
performed on the same image plane. As for the attenuation
measurements, the mean CT attenuation value of each
target lesion was measured in HUs by drawing a region of
interest covering as large an area as possible (at least two
thirds of the longest diameter) in the solid portion of the
target lesion. Necrotic areas were also included in the
attenuation value measurements. The attenuation
measurements were performed for the evaluation of the
percentage changes in the mean lesion attenuation or the
contrast enhancement changes before and after treatment
(designated as the combined criteria for evaluating both
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Table 1. Tumor Response According to Choi Criteria 
Response Definition
Complete response Disappearance of all lesions
No new lesions
Partial response Decrease in size* of ≥ 10% or decrease in tumor density (HU) ≥ 15% on CT
No new lesions
No obvious progression of non-target lesions
Stable disease Does not meet criteria for complete response, partial response or progressive disease
Progressive disease  Increase in tumor size of ≥ 10% and it does not meet criteria of partial response according to tumor
density (HU) on CT
New lesions 
Note.─ * Sum of longest diameters of target lesions as defined in RECIST (Reference 2)
Table 2. Best Response by Four Different Assessment Methods for Each Patient (Including Condition for Response
Confirmation) 
Patient  RECIST  RECIST  Alternative  Combined 
No. 1.1 Solid Method Criteria
Cavitation Reasons for Unavailable CT Attenuation Values
01S D S D S D P R
02S D S D P R S D Y e s
03S D S D S D P R
04P D P D P D P D
05S D S D S D S D
06S D S D S D P D
07P R P R P R P R
08 PR PR PR PR Disappeared solid component within partly solid nodule
09 SD SD PR SD Yes Cavitary change of entire solid component
10 PD PD PD PR Yes
11 SD SD SD PR
12 PD SD PD PD
13 SD SD PR PR Yes
14 SD SD PR PR
15 SD SD PR SD
16 PR PR PR PR Yes Cavitary change of entire solid component
Note.─ NA = not assessable, No. = number, PD = progressive disease, PR = partial response, RECIST = response evaluation criteria in solid tumor, 
SD = stable disease the changes of the tumor size and attenuation based on
Choi’s criteria [4]) (Table 1). If a lesion had a small solid
portion, then a region of interest of a 5 mm
2 area was not
applicable to measure the attenuation (e.g., a very thin
cavitary wall in a cavitary lesion or a very small tumor
after the treatment), and we were not able to measure the
attenuation values of such a lesion. In these conditions, size
measurements only were considered in the tumor response
assessment. All the other details regarding the definitions
for the designation of response and the assessment of non-
target lesions for the three different assessment methods
were identical to the RECIST version 1.1.
Assessment of Tumor Response and Follow-up 
First, response assessment was performed by using the
RECIST version 1.1 (2). Second, the tumor response was
evaluated according to RECIST with covering only the
solid component of the target lesions (RECISTsolid). Third,
an alternative response assessment (the alternative
method) was used to measure the tumor response and
particularly in the cavitary lesions; we calculate the
changes of the target lesion with including only the soft-
tissue wall thickness component and we excluded the air
component of cavitary change (subtracting the cavity
diameter from the longest diameter of the cancer mass) (3).
Finally, the combined criteria (Table 1) were applied for
tumor response evaluation (4), for which both the size and
attenuation changes on the enhanced scans before and
after treatment were computed for each target lesion.
Following independent interpretations by the two readers,
discordant reports were jointly reviewed by the two
readers and one third reader (with seven years of CT
interpretation experience), and a final consensus decision
was reached. 
After treatment, the patients were followed up at two
month intervals with chest and abdominal CT scans to
identify any disease progression. The patients were also
observed for survival until death or until the last contact if
still alive. The patients were classified as patients with a
complete response (CR), partial response (PR), stable
disease (SD) or progressive disease (PD) after treatment.
The good responders were deemed as the patients with a
Lee et al.
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Fig. 3. Progression free survival in subgroups of partial response, stable disease and progressive disease according to each response
criterion.
Although it was not statistically significant, prediction of response to vascular inhibitor therapy was better with using alternative method (p
= 0.07) than with using RECIST, RECISTsoild or combined criteria. 
PD = progressive disease, PFS = progression-free survival, PR = partial response, SD = stable diseaseCR or PR, and the good overall responders were deemed
as the patients showing a CR, PR or SD on the follow-up
CT. 
Statistic Analysis
Statistical analyses were performed with SPSS software
(SPSS for Windows, version 15.0, 2006; SPSS, Chicago,
IL), and significance was set at p values < 0.05.
Disease PFS was defined as the time from the starting
date of treatment until the time point of patient progres-
sion (as shown by radiologic [CT] and clinical examination)
or death from the disease. For the patients who had no
evidence of progressive disease, the absence of disease
progression was ascertained at the date of the last follow-
up examination. We determined how much the response
assessment would be altered if we applied the three differ-
ent assessment evaluation methods instead of the RECIST
method. To evaluate the capability of RECIST,
RECISTsolid, the alternative method and the combined
criteria to predict the patient prognosis, the PFSs were
compared between the responders (CR, PR, SD and PD) or
between the good and poor responders or between the
good and poor overall responders according to the four
different measurement methods. The comparisons were
conducted using a log-rank test. The interobserver
agreement between the two radiologists was assessed by
calculating the k value for response according to each
response criterion.
RESULTS
Difference among the Various Criteria
The details of the response designations by using the four
different assessment methods for each patient are
summarized in Table 2. Five patients in the trial of
bevacizumab-containing chemotherapy were found to
have cavitation within lesions after treatment. Marked
cavitation (to the degree that there was no residual solid
component) within the lesions occurred in two patients
(Fig. 2). 
Of the 16 patients, six RECIST poor responders would
have achieved a designation of PR by the combined
criteria. In the case of the alternative method, of the same
six patients, five patients would have been reclassified as
Targeted Therapy for Non-Small Cell Lung Cancer and New CT Response Criteria
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Fig. 4. Progression free survival in good and poor responders by each response criterion. 
Although it was not statistically significant, prediction of response to vascular inhibitor therapy was better with using alternative method (p
= 0.09) than with using RECIST, RECISTsoild or combined criteria. PFS = progression-free survivalPR and one as SD. The overall response rates (ORRs, the
patients showing a CR, PR or SD) according to RECIST,
RECISTsolid, the alternative method and the combined
criteria were 81%, 88%, 81%, and 81%, respectively. The
confirmed response rates (RRs, the patients showing a CR
or PR with the condition of response confirmation) were
19%, 19%, 50% and 56%, respectively.
Response Prediction
Although no significant difference was observed for the
PFS among the three (PR, SD and PD) response groups to
vascular inhibitor therapy, the alternative method showed
the biggest stratifying power among the three groups for
the prediction of PFS (p = 0.07) (Fig. 3). For the prognosis
between the good (CR or PR) and poor responders, the
alternative method again showed the biggest stratifying
power among the three groups for the prediction of PFS (p
= 0.09), yet there is no statistically significance (Fig. 4). The
RECIST and the alternative method showed a significant
difference for the prognosis between the good (CR, PR, or
SD) and poor overall responders (p = 0.02) (Fig. 5).
Interobserver Variability of the Measurements
The interobserver agreements between the two radiolo-
gists for the RECIST and the newly devised criteria that
reflected morphologic changes were all good (Table 3). The
interobserver agreement for the alternative method was
the best (κ = 0.79, 95% CI: 0.52-1.00), whereas that for
the combined criteria was the worst (κ = 0.68, 95% CI:
0.36-0.99). 
DISCUSSION
Evaluating a PR on an imaging study of solid tumors is
not easy (7-9). Molecular-targeted treatment has given rise
Lee et al.
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Fig. 5. Progression free survival in good and poor overall responders by each response criterion. 
RECIST and alternative method show significant difference for predicting prognosis between good and poor overall responders (p =
0.02). PFS = progression-free survival
Table 3. Interobserver Agreement for CT Review Using Four
Different Assessment Methods 
κ (95% CI)
RECIST 0.74 (0.41, 1.00)
RECISTsolid 0.69 (0.30, 1.00)
Alternative method 0.79 (0.52, 1.00)
Combined criteria 0.68 (0.36, 0.99)
Note.─ CI = confidence interval for corresponding statisticto a different antitumor effect from that of cytotoxic
therapy and so this may highlight the limitations of using
the size criteria alone for the assessment of a tumor
response to the target agent (5). Furthermore, the response
to bevacizumab, which has an antiangiogenic mechanism
of action, may be inadequately assessed by the traditional
size-based radiologic criteria (RECIST 1.0 or RECIST 1.1),
which were designed for assessing the reduction of the
tumor volume following the administration of cytotoxic
agents. We present here three novel CT criteria that reflect
the morphologic findings for predicting the response to
bevacizumab-containing chemotherapy in patients with
NSCLC. These criteria were reproducible, as was shown
by the good interobserver agreement for the assessment of
tumor response between the two independent radiologists.
Cavitation within a tumor may be a kind of tumor
response to cancer therapy, and especially to VEGF
receptor inhibitor therapy. Thus, the response evaluation
can be improved by incorporating cavitation into the
volume assessment for target lesions and this may change
important outcome-measurement parameters. In our study,
five patients were found to have cavitation in lesions after
treatment with bevacizumab therapy. In the case of Figure
2, the entire solid component was changed into an air-filled
thin-walled cystic lesion. However, the tumor response
was assessed as SD according to the traditional RECIST
method. In contrast, this patient achieved a PR according
to the alternative method. 
The combined criteria reflect the change of tumor
enhancement and this helped confirm that RECIST signifi-
cantly underestimated the tumor response. The decreased
attenuation values of the target lesions on CT after cancer
therapy histopathologically correspond to an area of tumor
necrosis or cystic degeneration. Comparing the results of
Figures 4 and 5, the discrepancies among the response
rates and overall response rates were mostly attributable
to the different definition of PR between the traditional
RECIST 1.1 and the combined criteria. In the combined
criteria, the lower-level cut-off value (from 30% in
RECIST 1.1 to 10% in the combined criteria) for a PR in
terms of a decreased tumor size is applied. With the
combined criteria, five SDs according to RECIST 1.1 could
be re-categorized as PRs. These five patients were in the
same overall good response group both according to the
RECIST 1.1 and the combined criteria (Fig. 5), yet they
were reclassified into the good response group according to
the combined criteria from the poor response group
according to the RECIST 1.1 (Fig. 4). This reclassification
better reflects the recently changed concept of SD; achiev-
ing SD has been identified as a potential surrogate end
point for an improved clinical outcome for epidermal
growth factor receptor-tyrosine kinase inhibitors (EGFR-
TKI) therapy. Currently, durable modest regression or
prolonged SD achieved by these agents is viewed as
evidence of antitumor activity (9). The recent studies that
assessed tumors’ responses to antiangiogenic agents with
using CT or MRI have focused on tumor perfusion (10,
11). However, the degree of tumor enhancement has been
consistently assessed because of variations in the scanning
techniques. The Choi criteria can be simply and efficiently
applied to response evaluation in daily practice, whereas
the tumor perfusion evaluation method, despite that it is a
sophisticated and accurate method, it requires repeated
scans over time and this may impose a potential radiation
hazard on patients who are undergoing CT perfusion
evaluation (4). 
The extent of ground-glass opacity in a peripheral lung
cancer and especially in an adenocarcinoma (a partly solid
nodule on CT scans) may be a prognosis determinant (6).
However, the extent of GGO within a partly solid lung
cancer does not vary much even after effective chemother-
apy. Only the solid component within a partly solid nodule
may show a response to cancer therapy, as is shown in
Figure 1. Therefore, the measurement of changes in the
solid component in the partly solid peripheral lung cancers
may reflect accurately the tumor response to chemother-
apy. Even though our results using the RECISTsolid
method did not show a significant result for the prediction
of PFS during bevacizumab therapy, this might have been
caused by too small a number of patients who had a partly
solid peripheral lung cancer.
When assessing a peripheral lung cancer response to
anticancer therapy, RECIST 1.0 or RECIST 1.1 do not
elaborate on the image viewing methods and specifically
on whether we should use the lung or mediastinal window
images of CT scans (1, 2). Thoracic radiologists conven-
tionally measure the tumor size on the lung window
images (including both the GGO and solid components in a
partly solid tumor). Yet as mentioned above, only the solid
component may show a response to anticancer therapy.
Thus, the mediastinal window images may be more
appropriate in the assessment of tumor response, and
particularly in peripheral lung cancers (partly solid
nodules).
Our study has some limitations. First, our study was a
retrospective study (although the patients were enrolled in
a prospective trial). Second, our results were based on a
small number of cases. Thus, our results may not represent
the overall results and they cannot be to freely general-
ized. Third, the applicability of these criteria should be
tested with other biologic agents other than bevacizumab
for treating NSCLC. 
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In conclusion, the response outcome evaluations using
three different CT response criteria reflecting tumor cavita-
tion, the GGO component and the attenuation changes in
NSCLC patients treated with bevacizumab showed differ-
ent results from that with using the traditional RECIST
method. Our results indicate that assessing the morpho-
logic characteristics, not to mention measuring the tumor
size, may reflect the more detailed changes within tumors
with this therapy and so give clinically useful response
information as a noninvasive surrogate marker for predict-
ing the prognosis. Further studies with a large number of
NSCLC patients are needed for developing new response
evaluation methods that combine and integrate the
changes of the morphologic and size characteristics of
target lesions. 
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